China has ​become a major source of new medicines and clinical research, ‌reshaping the global pharmaceutical-industry landscape, Pfizer Chief International Commercial Officer Alexandre de Germay said at an event hosted by industry lobby group the European Federation of Pharmaceutical Industries ​and Associations (EFPIA).

“Today, 40% of all clinical studies in oncology in ​the world are in China,” de Germay said. “The volume of ⁠innovation that is coming out of biotech in China is just amazing.”